Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy

被引:0
作者
Nikolina Vlatković
Mark T. Boyd
Carlos P. Rubbi
机构
[1] University of Liverpool,Cancer Research Centre
来源
Cellular and Molecular Life Sciences | 2014年 / 71卷
关键词
Nucleolus; p53; MDM2; Stress; Ribosome; Cancer therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Nucleoli perform a crucial cell function, ribosome biogenesis, and of critical relevance to the subject of this review, they are also extremely sensitive to cellular stresses, which can cause loss of function and/or associated structural disruption. In recent years, we have learned that cells take advantage of this stress sensitivity of nucleoli, using them as stress sensors. One major protein regulated by this role of nucleoli is the tumor suppressor p53, which is activated in response to diverse cellular injuries in order to exert its onco-protective effects. Here we discuss a model of nucleolar regulation of p53, which proposes that key steps in the promotion of p53 degradation by the ubiquitin ligase MDM2 occur in nucleoli, thus providing an explanation for the observed link between nucleolar disruption and p53 stability. We review current evidence for this compartmentalization in p53 homeostasis and highlight current limitations of the model. Interestingly, a number of current chemotherapeutic agents capable of inducing a p53 response are likely to do so by targeting nucleolar functions and these compounds may serve to inform further improved therapeutic targeting of nucleoli.
引用
收藏
页码:771 / 791
页数:20
相关论文
共 50 条
  • [1] Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy
    Vlatkovic, Nikolina
    Boyd, Mark T.
    Rubbi, Carlos P.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2014, 71 (05) : 771 - 791
  • [2] p53 mutants - The Achilles' heel of human cancers?
    Brachmann, RK
    CELL CYCLE, 2004, 3 (08) : 1030 - 1034
  • [3] Ribosomal Proteins Control or Bypass p53 during Nucleolar Stress
    Russo, Annapina
    Russo, Giulia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (01):
  • [4] p53 as a hub in cellular redox regulation and therapeutic target in cancer
    Eriksson, Sofi E.
    Ceder, Sophia
    Bykov, Vladimir J. N.
    Wiman, Klas G.
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) : 330 - 341
  • [5] p53 as a drug target in cancer therapy
    Chène, P
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (06) : 923 - 935
  • [6] The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy
    Woods, Simone J.
    Hannan, Katherine M.
    Pearson, Richard B.
    Hannan, Ross D.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2015, 1849 (07): : 821 - 829
  • [7] p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53
    Fojo, T
    DRUG RESISTANCE UPDATES, 2002, 5 (05) : 209 - 216
  • [8] The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer
    Farnebo, Marianne
    Bykov, Vladimir J. N.
    Wiman, Klas G.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 396 (01) : 85 - 89
  • [9] p53 as a target for the treatment of cancer
    Duffy, Michael J.
    Synnott, Naoise C.
    McGowan, Patricia M.
    Crown, John
    O'Connor, Darran
    Gallagher, William M.
    CANCER TREATMENT REVIEWS, 2014, 40 (10) : 1153 - 1160
  • [10] p53 signaling in cancer progression and therapy
    Marei, Hany E.
    Althani, Asmaa
    Afifi, Nahla
    Hasan, Anwarul
    Caceci, Thomas
    Pozzoli, Giacomo
    Morrione, Andrea
    Giordano, Antonio
    Cenciarelli, Carlo
    CANCER CELL INTERNATIONAL, 2021, 21 (01)